VIENNALAB - Established innovations in diagnostics

HLA-B5701 is a genetic risk factor for hypersensitivity reactions to abacavir, an antiretroviral drug used in HIV therapy. The HLA-B5701 RealFast™ Assay discriminates the presence or absence of HLA-B5701 in HIV-infected patients and anterior uveitis.


  • Approximately 5% to 8% of HIV-infected Caucasians undergoing abacavir treatment develop severe multisystem side effects.
  • Immediate and permanent discontinuation of treatment leads to a rapid reversal of symptoms.
  • Screening of patients for the presence of HLA-B5701 before starting therapy reduces the incidence of hypersensitivity reactions due to abacavir.

Product Details

HLA-B5701 RealFast™ Assay ref7-610 7-613